Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4981 AL 4995

Unveiling a prescribing cascade in an older man

Rosenberg J, Rochon PA, Gill SS.

J Am Geriatr Soc. 2014 Mar;62(3):580-1. doi: 10.1111/jgs.12714.

Rationale and clinical data supporting nutritional intervention in Alzheimer's disease

Engelborghs S, Gilles C, Ivanoiu A, Vandewoude M.

Acta Clin Belg. 2014 Jan-Feb;69(1):17-24. doi: 10.1179/0001551213Z.0000000006.

Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs

Talbot K.

Neurodegener Dis Manag. 2014;4(1):31-40. doi: 10.2217/nmt.13.73.

From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?

Flaten V, Laurent C, Coelho JE, Sandau U, Batalha VL, Burnouf S, Hamdane M, Humez S, Boison D, Lopes LV, Buée L, Blum D.

Biochem Soc Trans. 2014 Apr;42(2):587-92. doi: 10.1042/BST20130229.

Considering a new paradigm for Alzheimer's disease research

Langley GR.

Drug Discov Today. 2014 Aug;19(8):1114-24. doi: 10.1016/j.drudis.2014.03.013. Epub 2014 Mar 21.

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L.

J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690.

Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail?

Persson T, Popescu BO, Cedazo-Minguez A.

Oxid Med Cell Longev. 2014;2014:427318. doi: 10.1155/2014/427318. Epub 2014 Jan 5.

Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets

Zádori D, Veres G, Szalárdy L, Klivényi P, Toldi J, Vécsei L.

J Alzheimers Dis. 2014;42 Suppl 3:S177-87. doi: 10.3233/JAD-132621.

Formulations: friendly, fast, forgiving and flexible

Citrome L.

Int J Clin Pract. 2014 Apr;68(4):407. doi: 10.1111/ijcp.12420.

Treadmill training as an augmentation treatment for Alzheimer's disease: a pilot randomized controlled study

Arcoverde C, Deslandes A, Moraes H, Almeida C, Araujo NB, Vasques PE, Silveira H, Laks J.

Arq Neuropsiquiatr. 2014 Mar;72(3):190-6. doi: 10.1590/0004-282X20130231.

Gait changes with anti-dementia drugs: a prospective, open-label study combining single and dual task assessments in patients with Alzheimer's disease

Beauchet O, Launay CP, Allali G, Herrmann FR, Annweiler C.

Drugs Aging. 2014 May;31(5):363-72. doi: 10.1007/s40266-014-0175-3.

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease

Ghosh AK, Osswald HL.

Chem Soc Rev. 2014 Oct 7;43(19):6765-813. doi: 10.1039/c3cs60460h.

A new regulatory road-map for Alzheimer's disease drug development

Becker RE, Greig NH.

Curr Alzheimer Res. 2014 Mar;11(3):215-20. doi: 10.2174/156720501103140329210642.

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease

Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2014 Apr 29;82(17):1536-42. doi: 10.1212/WNL.0000000000000364. Epub 2014 Apr 2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias